CF
JBIO

Corebridge Financial’s Jade Biosciences JBIO Stock Holding History

Corebridge Financial’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-189
Closed -$16.6K – 277
2025
Q1 		$16.6K Sell
189
-3
-2% -$264 ﹤0.01% 2930
2024
Q4 		$17.8K Sell
192
-14
-7% -$1.21K ﹤0.01% 2971
2024
Q3 		$15.1K Sell
206
-1
-0.5% -$65 ﹤0.01% 2996
2024
Q2 		$12K Buy
+207
New +$137K ﹤0.01% 3023

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Corebridge Financial's JBIO Position: Q2 2025 in Review

Corebridge Financial sold out of Jade Biosciences (JBIO) in Q2 2025, closing a stake of 189 shares — an estimated $16.6K sold.

Corebridge Financial first reported a position in JBIO in Q2 2024 and held it in 4 quarters. The position peaked at $17.8K in Q4 2024. 75 funds tracked by Wall St. Rank hold JBIO as of Q2 2025.

  • Corebridge Financial reported no remaining Jade Biosciences position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 189 Jade Biosciences shares in Q2 2025, an estimated $16.6K.
  • Corebridge Financial first reported a position in Jade Biosciences in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Jade Biosciences position peaked at $17.8K in Q4 2024.
  • 75 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.